Lifesci Capital Predicts Stronger Earnings for Disc Medicine

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Equities researchers at Lifesci Capital upped their FY2024 earnings estimates for Disc Medicine in a report released on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now expects that the company will earn ($3.92) per share for the year, up from their previous forecast of ($4.33). The consensus estimate for Disc Medicine's current full-year earnings is ($4.15) per share. Lifesci Capital also issued estimates for Disc Medicine's Q4 2024 earnings at ($0.94) EPS.

Several other brokerages have also commented on IRON. HC Wainwright raised their price objective on shares of Disc Medicine from $70.00 to $118.00 and gave the stock a "buy" rating in a report on Wednesday. Cantor Fitzgerald restated an "overweight" rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Tuesday, October 15th. Morgan Stanley upgraded shares of Disc Medicine from an "equal weight" rating to an "overweight" rating and set a $85.00 price objective for the company in a report on Tuesday, November 5th. Raymond James upgraded shares of Disc Medicine from an "outperform" rating to a "strong-buy" rating and raised their price objective for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Finally, Wedbush restated an "outperform" rating and issued a $83.00 price objective (up from $75.00) on shares of Disc Medicine in a report on Tuesday. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $85.80.

Disc Medicine Stock Down 2.0 %

Shares of Disc Medicine stock traded down $1.21 during trading on Friday, reaching $59.46. 270,748 shares of the stock were exchanged, compared to its average volume of 355,189. The stock's fifty day moving average is $51.20 and its 200 day moving average is $44.97. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -14.94 and a beta of 0.60. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $77.60.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($1.04) by $0.15.

Institutional Investors Weigh In On Disc Medicine

A number of large investors have recently added to or reduced their stakes in IRON. Atlas Venture Life Science Advisors LLC lifted its stake in shares of Disc Medicine by 9.7% during the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company's stock valued at $113,101,000 after buying an additional 222,223 shares in the last quarter. Wellington Management Group LLP increased its holdings in Disc Medicine by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company's stock valued at $90,429,000 after acquiring an additional 83,731 shares during the last quarter. Frazier Life Sciences Management L.P. increased its holdings in Disc Medicine by 123.5% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company's stock valued at $79,090,000 after acquiring an additional 969,834 shares during the last quarter. Deerfield Management Company L.P. Series C increased its holdings in Disc Medicine by 53.8% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company's stock valued at $46,119,000 after acquiring an additional 357,730 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Disc Medicine by 59.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company's stock valued at $58,788,000 after acquiring an additional 353,382 shares during the last quarter. Institutional investors own 83.70% of the company's stock.

Insider Activity at Disc Medicine

In other Disc Medicine news, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 7,538 shares of company stock valued at $437,875 over the last 90 days. Corporate insiders own 4.24% of the company's stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.